What is PrimBio?
PrimBio, established in 2011, is at the forefront of personalized medicine, leveraging genomic innovation to offer advanced research services and clinical tests, including critical cancer diagnostics. The company has built a strong reputation for delivering high-quality COVID-19 RT PCR testing with rapid turnaround times, providing individuals with travel-ready results. Their commitment extends to collaborating with health authorities on initiatives such as COVID-19 genome sequencing, positioning them as a key player in both public health and precision healthcare.
How much funding has PrimBio raised?
PrimBio has raised a total of $89K across 1 funding round:
Debt
$89K
Debt (2021): $89K with participation from PPP
Key Investors in PrimBio
PPP
Public-Private Partnership
What's next for PrimBio?
With significant backing at a Series B/C stage, PrimBio is poised for accelerated growth and enhanced service delivery. The substantial expansion capital is expected to fuel further development in genomic technologies, broaden their diagnostic capabilities, and potentially expand their reach in both research and clinical markets. This strategic investment signals confidence in PrimBio's model for advancing personalized medicine and its role in addressing critical health needs.
See full PrimBio company page
